CNPOF:OTC-RIV Capital Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | OTC

Last Closing Price

USD 2.54

Change

+0.03 (+1.20)%

Market Cap

USD 0.34B

Volume

0.46M

Average Target Price

USD 2.75 (+8.27%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Canopy Rivers Inc. is a venture capital firm. The firm is a stage agnostic, with seed to sale, although it prefers to invest in series A to C rounds. It prefers to make investments in cannabis sector with focus on burgeoning marijuana companies and sectors like agriculture and food sciences, production, processing, pharmaceuticals and biotechnology, software and data, hardware, consumer products and accessories, wellness products, retail and distribution, and media and content. The firm also focuses on beverages, capsules and concentrates, edibles, dry flower / pre-rolls, vaporizers and hardware, pet products, and topicals. In agriculture and food sciences firm focuses in invest plant science, soil science, food science, animal science and environmental science. In production firm focuses in Indoor cultivation, greenhouse cultivation, outdoor cultivation, nursery cultivation and fermentation. In processing firm focuses in harvesting, extraction and purification, packaging, food and beverage processing and laboratory testing services. In pharmaceuticals and biotechnology firm focuses in pharmaceutical discovery and development, delivery method (ex: pill, soft gel, tincture), biosynthetic derived cannabinoids and other molecules, medical devices (ex: inhalers) and lab equipment. In consumer products and accessories firm focuses in edibles, beverages, inhalable, cosmetics and cannabis consumption accessories. In retail and distribution firm focuses in licensed brick and mortar retailers, pharmacies, online consumer marketplaces, delivery services, and others. The firm invests in opportunities globally. The firm prefers to invest in check sizes have ranged from CA$1 million ($0.71 million) to $40 million ($28.45 million), but more typical investment range is between CA$5 million ($3.6 million) to CA$10 million ($7.1 million). The firm is focused on making minority stake investments. Firm employ diverse investment structures including debt, preferred and common equity, and production-linked royalties. Canopy Rivers In

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-02 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BAYP Bayport International Holdings..

+1.91 (+26.53%)

USD97.63B N/A N/A
MKGAF MERCK Kommanditgesellschaft au..

-1.88 (-1.13%)

USD72.43B 32.13 17.34
MKKGY MERCK Kommanditgesellschaft au..

-0.17 (-0.52%)

USD71.81B 31.73 17.34
TKPHF Takeda Pharmaceutical Company ..

N/A

USD53.48B 20.90 0.10
ESALY Eisai Co., Ltd

-0.73 (-1.05%)

USD19.77B 33.46 0.13
ESALF Eisai Co., Ltd

N/A

USD19.71B 34.36 0.13
SFOSF Shanghai Fosun Pharmaceutical ..

-0.15 (-3.16%)

USD17.36B 28.11 3.30
SGIOF Shionogi & Co., Ltd

+0.05 (+0.10%)

USD15.71B 15.85 0.07
SGIOY Shionogi & Co., Ltd

-0.06 (-0.46%)

USD15.62B 1.96 0.07
TEVJF Teva Pharmaceutical Industries..

N/A

USD12.37B 900.00 16.02

ETFs Containing CNPOF

Symbol Name Weight Mer Price(Change) Market Cap
YOLO AdvisorShares Pure Cannab.. 0.00 % 0.75 %

+0.02 (+0.08%)

USD0.16B
CNBS Amplify Seymour Cannabis .. 0.00 % 0.75 %

-0.57 (-1.80%)

N/A
THCX The Cannabis ETF 0.00 % 0.70 %

+0.09 (+0.43%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 176.15% 77% C+ 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 176.15% 77% C+ 87% B+
Trailing 12 Months  
Capital Gain 264.37% 74% C 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 264.37% 74% C 82% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -25.63% 22% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.63% 22% F 5% F
Risk Return Profile  
Volatility (Standard Deviation) 51.64% 61% D- 42% F
Risk Adjusted Return -49.64% 25% F 16% F
Market Capitalization 0.34B 83% B 60% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 9.15 50% F 68% D+
Price/Book Ratio 1.38 66% D 56% F
Price / Cash Flow Ratio -43.86 89% B+ 90% A-
EV/EBITDA 3.44 47% F 53% F
Management Effectiveness  
Return on Equity -44.83% 50% F 19% F
Return on Invested Capital -3.97% 58% F 33% F
Return on Assets -10.78% 58% F 31% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.80 28% F 21% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.